Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC).
Please join expert faculty discussing highlights of a satellite symposium held June 4, 2016 at the annual oncology meeting that explores the current and expanding pool of information about these agents, as well as best practices for their current and potential use in MBC.
Advertisement